Soligenix (NASDAQ:SNGX) posted its earnings results on Friday. The biopharmaceutical company reported ($0.11) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.11), MarketWatch Earnings reports. Soligenix had a negative return on equity of 176.04% and a negative net margin of 120.14%. The firm had revenue of $1.40 million for the quarter, compared to analysts’ expectations of $1.40 million.
Soligenix stock traded down $0.04 during midday trading on Friday, reaching $1.10. The company had a trading volume of 140,125 shares, compared to its average volume of 219,986. Soligenix has a 12-month low of $0.91 and a 12-month high of $3.70.
A number of equities research analysts have recently commented on the company. ValuEngine upgraded Soligenix from a “hold” rating to a “buy” rating in a research report on Thursday, November 1st. Maxim Group restated a “buy” rating and set a $4.00 target price on shares of Soligenix in a research report on Thursday, September 13th.
In related news, Director Mark E. Pearson purchased 170,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 17th. The shares were purchased at an average cost of $1.16 per share, with a total value of $197,200.00. Following the purchase, the director now owns 2,500,000 shares of the company’s stock, valued at approximately $2,900,000. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders purchased a total of 182,230 shares of company stock worth $212,392 over the last ninety days. 5.03% of the stock is currently owned by corporate insiders.
WARNING: “Soligenix (SNGX) Releases Earnings Results, Hits Expectations” was first published by Stock Observer and is the property of of Stock Observer. If you are viewing this news story on another site, it was stolen and reposted in violation of international trademark & copyright law. The original version of this news story can be read at https://www.thestockobserver.com/2018/11/10/soligenix-sngx-releases-earnings-results-hits-expectations.html.
Soligenix, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, BioTherapeutics and Vaccines/BioDefense. The BioTherapeutics segment develops SGX301, a photodynamic therapy, which is in Phase III clinical trial to treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that has completed Phase II clinical trial to treat oral mucositis in head and neck cancer.
Recommended Story: Outstanding Shares and The Effect on Share Price
Receive News & Ratings for Soligenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soligenix and related companies with MarketBeat.com's FREE daily email newsletter.